Explosive growth of antidiabetic SGLT-2 inhibitors, exceeding KRW 10 billion sales

Antidiabetic SGLT-2 inhibitors have continued explosive growths.

Currently, drugs which have been launched in the market with the health insurance benefit are AstraZeneca’s ‘Forxiga’ and Astellas’s Suglat.

When it comes to the two drugs, Forxiga is about to become a blockbuster as exceeding KRW 10 billion last year, and Suglat is also growing at furious speed.

Since SGLT-2 inhibitors have no...